Frontiers in Psychiatry (Aug 2022)
Depression is differentially related to cognitive and biomarker outcomes among Mexican Americans
Abstract
IntroductionDespite tremendous advancements in the research of Alzheimer’s disease (AD), Mexican Americans, who reflect 65% of the US Hispanic community, remain severely underrepresented in research. Our data demonstrate that risk factors for, and biomarkers of, AD are different among Mexican Americans as compared with non-Hispanic whites. Here, we examined the impact of depressive symptoms on cognitive and AD-relevant biomarker outcomes among the Mexican Americans.MethodsData were examined from 1,633 (852 Mexican Americans and 781 non-Hispanic whites) of the Health and Aging Brain Study–Health Disparities (HABS–HD). Depression was assessed using the Geriatric Depression Scale while cognition was measured using detailed neuropsychological testing. Plasma biomarkers of Aβ40, Aβ42, total tau, and NfL were examined in addition to MRI-based neurodegeneration. PET amyloid data were available in a subset of participants.ResultsDepressive symptoms were significantly associated with cognitive testing results among both Mexican Americans and non-Hispanic whites. However, depression was only significantly associated with cognitive outcomes and plasma biomarkers among the Mexican American APOEε4 non-carriers.DiscussionDepressive symptoms are more commonly endorsed by Mexican Americans and these symptoms are more strongly associated with cognitive and AD-biomarker outcomes among this ethnic group. However, depression scores were only related to AD outcomes among APOEε4 non-carriers within the Mexican American group. These findings can aid in the development of a population-informed precision medicine for treating and preventing cognitive loss among the Mexican Americans.
Keywords
